spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Signant Health Launches Partner Program to Team with Clinical Research Organizations (CROs) Committed to Improving Clinical Trials with Patient-Centric Technology

Signant Health

Collaborative program helps CROs deliver additional value to sponsors with best practices for Patient Data, Patient Experience, Clinical Supplies, and Endpoint Quality Solutions

Chris Crucitti, Chief Commercial Officer of Signant Health explains: “This program puts in place the infrastructure needed to ensure the success of our CRO partners across Signant’s solution portfolio. We will remain ever committed to the traditional support of our partners via protocol design and optimization, eCOA data collection, data quality oversight, patient engagement, eConsent and clinical supply management. However, the needs and challenges of CROs are more complex and expansive today than ever before, just as they are for the sponsors we jointly support. The time is right for us to make a landmark investment in our partners so that together we can more powerfully impact data quality and clinical trial execution. When our partners succeed, clinical research succeeds.”

With approximately 50 percent of clinical research activities being outsourced by pharmaceutical companies to CROs that offer full services across the entire drug development process, there is both a growing need for CROs to deliver technology in support of services and an increasing demand to leverage technology to differentiate those services. This Partner Program is designed to extend Signant’s 20 years of experience—in clinical and scientific practices, operations, and global requirements—to its partners, allowing CROs to deliver the highest quality endpoint data across its solutions.

As a Signant partner, CROs will gain commercial and operational advantages including exclusive commercial terms, business development support, joint marketing, clinical & scientific expertise, product training and dedicated resources for governance.

To learn more about the Signant Health Partner Program visit signanthealth.com/partners

Who Is Signant Health?

The best technology succeeds in the background. Signant Health (formerly CRF Health and Bracket) provides solutions that simplify every step of the patient journey to make it easier for people to participate in, and for sites and study teams to run, clinical trials. Signant unites eCOA, eConsent, Patient Engagement, IRT, Clinical Supplies and Endpoint Quality into the industry’s most comprehensive patient-centric suite – an evolution built on more than 20 years of proven clinical research technology. Our intense focus on the patient experience, deep therapeutic area expertise and global operational scale enable hundreds of sponsors and CROs (including all Top 20 pharma) to extend the reach of drug development, expand patient opportunities and improve data quality – helping them bring life-changing therapies to our families and communities around the world. Take a significant step toward patient-centricity at signanthealth.com.

CRF Health and Bracket are now Signant Health.

Contact: media@signanthealth.com, +1 267.498.2350

https://www.linkedin.com/company/signant-health/
 


phone +1 267 498 2300
email media@signanthealth.com
web https://signanthealth.com/
email 4000 Chemical Road Suite 300 Plymouth Meeting, PA 19462
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Switzerland overtakes Germany as Europe’s biggest drug delivery innovator, with the UK and France close behind

Paris, 19th August 2019: As predicted by the ‘European drug delivery and packaging’ report earlier this year, new data shows innovation in drug delivery is accelerating across Europe – with provisional findings from the Pharmapack Innovation Index (2020) showing that Switzerland has over taken Germany as Europe’s most innovative drug delivery market.
More info >>


White Papers

Pharmacovigilance and Risk Management Information in Centralised Applications in the EU

United BioSource Corporation (UBC)

Getting a new medication approved for the EU market through the centralised procedure can be complex and needs expertise. The new EU pharmacovigilance legislation (Good Vigilance Practice, GVP) is now in effect and applicants need to be fully compliant. It is critical to have a thorough understanding of the regulatory process and requirements, and the expectations with regards to the pharmacovigilance system and the risk management plan. Ensuring consistency and an appropriate level of detail in the documentation submitted as part of the approval process will help prevent unnecessary delays.
More info >>

Industry Events

ESMO Targeted Anticancer Therapies Congress 2020

2-4 March 2020, Paris, France

A unique and international mix of experts, researchers and decision makers both from academia and industry across the globe, will convene in Paris for a three-day Congress aiming at exchanging knowledge, experience and research innovations in cancer. TAT 2020 will focus, among others, on novel strategies in immuno-oncology, personalised medicine and molecular tumour boards, preclinical studies to identify effective combination therapies, use of microbiome, tumour agnostic trials, ADC technology, oncolytics, multispecific biological constructs and targeting cytokines. Participating in TAT 2020 will offer you the possibility to take part in interdisciplinary discussions inspiring new ideas and new collaborations.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement